Markus Warmuth
CEO, President at Monte Rosa Therapeutics, Inc. (GLUE)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $951K
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Jul 17SEC | GLUEMonte Rosa Therapeutics, Inc. | Sell | 9,500585,038 held (−2%) | $23.18 | $220K | -55.6% |
| Jun 2SEC | GLUEMonte Rosa Therapeutics, Inc. | Sell Plan | 4,998595,006 held (−1%) | $19.41 | $97K | -46.9% |
| Jun 2SEC | GLUEMonte Rosa Therapeutics, Inc. | Sell Plan | 468594,538 held (−0%) | $19.73 | $9K | -47.8% |
| May 5SEC | GLUEMonte Rosa Therapeutics, Inc. | Sell Plan | 5,467600,004 held (−1%) | $18.92 | $103K | -45.6% |
| Apr 15SEC | GLUEMonte Rosa Therapeutics, Inc. | Sell | 8,000605,471 held (−1%) | $17.64 | $141K | -41.6% |
| Mar 4SEC | GLUEMonte Rosa Therapeutics, Inc. | Sell Plan | 5,466613,471 held (−1%) | $17.92 | $98K | -42.5% |
| Jan 9SEC | GLUEMonte Rosa Therapeutics, Inc. | Sell Plan | 3,707620,696 held (−1%) | $23.24 | $86K | -55.7% |
| Jan 9SEC | GLUEMonte Rosa Therapeutics, Inc. | Sell Plan | 1,450619,246 held (−0%) | $23.88 | $35K | -56.9% |
| Jan 9SEC | GLUEMonte Rosa Therapeutics, Inc. | Sell Plan | 309618,937 held (−0%) | $24.57 | $8K | -58.1% |
| Jan 5SEC | GLUEMonte Rosa Therapeutics, Inc. | Sell | 10,135624,403 held (−2%) | $15.17 | $154K | -32.1% |
- Sell
CEO, President Markus Warmuth sold $97K of GLUE at $19.41 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Markus Warmuth sold $9K of GLUE at $19.73 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Markus Warmuth sold $103K of GLUE at $18.92 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Markus Warmuth sold $98K of GLUE at $17.92 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Markus Warmuth sold $86K of GLUE at $23.24 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Markus Warmuth sold $35K of GLUE at $23.88 — pre-scheduled 10b5-1 plan sale.